Comments
Mylan and Biocon have agreed to accelerate introduction of adalimumab biosimilar in Europe through Mylan’s in-licensing arrangement with Fujifilm Kyowa Kirin Biologics (FKB).
The product is at an advanced stage of review and could receive approval in H2 of 2018 in Europe.
Mylan could commercialise FKB’s Adalimumab in EU. Biocon retains economic interest in the deal in line with its existing collaboration with Mylan for monoclonal antibodies.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.